One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The value of patient-reported outcome measures for multiple sclerosis
Marisa P McGinley , Brittany Lapin
doi : 10.1177/13524585221111675
Volume 28 Issue 10, September 2022
Serum neurofilament light in MS: The first true blood-based biomarker?
Simon Thebault, Gauruv Bose , Ronald Booth Mark S Freedman
doi : 10.1177/1352458521993066
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Yes
Carlos Navas
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No
Dalia L Rotstein
All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: Commentary
Özgür Yaldizli,Tobias Derfuss
The expansion and severity of chronic MS lesions follows a periventricular gradient
Samuel Klistorner Michael H Barnett Stuart L Graham Chenyu Wang Alexander Klistorner
Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS
Biao Xiang Matthew R Brier Manasa Kanthamneni Jie Wen Abraham Z Snyder Dmitriy A Yablonskiy Anne H Cross
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial
Douglas L Arnold Daniela Piani-Meier Amit Bar-Or Ralph HB Benedict Bruce AC Cree Gavin Giovannoni Ralf Gold Patrick Vermer
Olfactory threshold predicts treatment response in relapsing multiple sclerosis
Gabriel Bsteh Harald Hegen Klaus Berek Patrick Altmann Michael Auer Franziska Di Pauli Lukas Haider Fritz Le
Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome
Eva-Maria Wendel Annikki Bertolini Lampros Kousoulos Markus Rauchenzauner Kathrin Schanda Andreas Wegener-Panzer Matthias Baumann Markus
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Jutta G?rtner Stephen L Hauser Amit Bar-Or Xavier Montalban Jeffrey A Cohen Anne H Cross Kumaran Deiva Habib
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Stephen L Hauser Anne H Cross Kevin Winthrop Heinz Wiendl Jacqueline Nicholas Sven G Meuth Paul S Giacomini
Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
Bruce AC Cree Douglas L Arnold Robert J Fox Ralf Gold Patrick Vermersch Ralph HB Benedict Amit Bar-Or Daniel
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials
Eva MM Strijbis Pavle Repovic Jop Mostert James D Bowen Bernard MJ Uitdehaag Gary Cutter Marcus W Koch
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES)
Morten Riemenschneider Lars G Hvid Steffen Ringgaard Mikkel Karl Emil Nygaard Simon Fristed Eskildsen Tobias
Association of pregnancies with risk of multiple sclerosis
Christiane Gasperi Alexander Hapfelmeier Antonius Schneider Klaus A Kuhn Ewan Donnachie Link to ORCID Bernhard Hemmer
Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study
Andrea Ines Ciplea Anna Kurzeja Sandra Thiel Sabrina Haben Jessica Alexander Evelyn Adamus Kerstin Hellwig
A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma
David S Rogawski Jeffrey J Nirschl Jamie McDonald Esther Nie Nicholas U Schwartz Hannes Vogel Brian J Scott Carl A Gold Lucas B Kipp
It is imperative to reconsider the concept of seronegative NMOSD
Romain Marignier
No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants
Benjamin Meir Jacobs Cameron Watson Charles Marshall Alastair Noyce Ruth Dobson
Response: No evidence for association between polygenic risk for multiple sclerosis and MRI phenotypes in approximately 30,000 healthy adult UK Biobank participants
C Louk de Mol Rinze F Neuteboom Philip R Jansen Tonya White
